Darrell D Belke from La Jolla, CA, age 63

view source

Location:

San Diego, CA

Industry:

Research

Work:

UCSD
Associate Project Scientist

Use Of Calcium Binding Proteins To Improve Cardiac Contractile Function
view source
US Patent:

20070041942, Feb 22, 2007
Filed:

Jun 28, 2004
Appl. No.:

10/562524
Inventors:

Wolfgang Dillmann - Solana Beach CA, US
Jorge Suarez - San Diego CA, US
Darrell Belke - San Diego CA, US
Bernd Gloss - Chapel Hill NC, US
International Classification:

A61K 48/00
C12N 15/861
G01N 33/53
US Classification:

424093200, 435456000, 435007100
Abstract:

Methods useful in the regulation of myocardial contraction are disclosed. The methods are useful in the regulation of heart function. The invention reveals that sorcin overexpression enhances cardiac contractile performance and establishes the concept of sorcin as a regulator of myocardial contractility. The invention also provides screening assays that allow for the identification of agents that modulate sorcin expression. Such agents are useful, for example, for diagnosing cardiac contractile function associated disorders in subjects, and treating the subjects with the agents identified as being able to modulate sorcin expression.

Compositions And Methods For Improving Heart Function
view source
US Patent:

20080313753, Dec 18, 2008
Filed:

Aug 25, 2005
Appl. No.:

11/574232
Inventors:

Wolfgang Dillmann - Solana Beach CA, US
Darrell H. Belke - San Diego CA, US
Ying Hu - San Diego CA, US
Raymond Clark - San Marcos CA, US
Assignee:

Regents of the University of California - Oakland CA
International Classification:

A01K 67/00
A61K 31/7088
A61K 38/00
A61K 35/12
C12N 5/00
US Classification:

800 15, 514 44, 514 2, 424 9321, 435325, 800 13, 800 18, 800 16, 800 17, 800 14
Abstract:

The present invention relates to treating or ameliorating heart disease associated with poor myocardial performance, e.g., diabetic cardiomyopathy and associated disorders, particularly to treating, preventing or ameliorating such disorders through inhibition of O-GlcNAcylation and/or increased activity of O-GlnNAcase. The invention provides vectors for gene transfer of O-GlnNAcase. In one aspect, the invention provides cells, vectors, formulations comprising them and methods of using them, for the gene transfer of the human O-GlnNAcase gene, e.g., to treat conditions and diseases associated with impaired cardiac contractility, such as that, found associated with diabetic cardiomyopathy. In another aspect, the invention provides non-human transgenic animals and host cells comprising genetically engineered cells having increased activity of O-GlnNAcase.

Darrell D Belke